<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00207792</url>
  </required_header>
  <id_info>
    <org_study_id>GCSF</org_study_id>
    <nct_id>NCT00207792</nct_id>
  </id_info>
  <brief_title>Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation</brief_title>
  <official_title>Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre National de Greffe de Moelle Osseuse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre National de Greffe de Moelle Osseuse</source>
  <brief_summary>
    <textblock>
      The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone
      marrow transplantation is well recognized. Recent laboratory studies demonstrated that these
      cytokines may also modify T-cell and dendritic cell function, but whether the effect is
      strong enough to alter the risk of graft-versus-host disease (GvHD) is unclear.

      The aim of this randomised study is to determine the effect of granulocyte colony-stimulating
      factor [G-CSF] (Neupogen; filgrastim) on the risk of acute GvHD after allogeneic bone marrow
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Graft vs Host Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: &gt; 16 years and &lt; 46 years

          -  Geno-identical allogeneic bone marrow transplantation

          -  Myeloablative conditioning regimen

          -  Haematological malignancies and acquired aplastic anemia

          -  Written and informed consent

        Exclusion Criteria:

          -  ECOG performance score &gt; 2

          -  T-cell depletion

          -  Serum creatinine level &gt; 133 Âµmol/L

          -  Abnormal liver function

          -  Positive HIV test

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek Ben Othman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre National de Greffe de Moelle Osseuse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tarek Ben Othman, MD</last_name>
    <phone>98901456</phone>
    <phone_ext>00216</phone_ext>
    <email>benothman-t@mailcity.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre National de Greffe de Moelle Osseuse</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Ben Othman, MD</last_name>
      <phone>98901456</phone>
      <phone_ext>00216</phone_ext>
      <email>benothman-t@mailcity.com</email>
    </contact>
    <investigator>
      <last_name>Tarek Ben Othman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>November 5, 2007</last_update_submitted>
  <last_update_submitted_qc>November 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2007</last_update_posted>
  <keyword>Granulocyte colony stimulating factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

